Assess Immune Persistence and Memory by Giving Plain PRP,PSA and PSC (10 Mths Age), and Immunogenicity and Safety of a Tritanrix (TM) HBV/Hib-MenAC/ Tritanrix(TM)-HBV/Hib2.5 Booster (15-18 Mths Age) in Previously Primed Subjects.

Trial Profile

Assess Immune Persistence and Memory by Giving Plain PRP,PSA and PSC (10 Mths Age), and Immunogenicity and Safety of a Tritanrix (TM) HBV/Hib-MenAC/ Tritanrix(TM)-HBV/Hib2.5 Booster (15-18 Mths Age) in Previously Primed Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Hib-DTP-hepatitis B-meningococcal vaccine groups A and C conjugate (Primary) ; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix)
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal infections; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 30 Sep 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00317174).
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top